CDE | Jotup

Cargill Awards More Than $3 Million Grant to National FFA Organization

Retrieved on:

Tuesday, March 19, 2024

EDI, Conference, Agriculture, Partnership, Travel, Diversity, Food, CDE, Student, Emerging market, Curriculum, FFA

INDIANAPOLIS, March 19, 2024 /PRNewswire-PRWeb/ -- Cargill awarded a three-year grant of $3.15 million to the National FFA Organization in support of its commitment to shape future agriculture leaders.

Key Points:

Cargill awarded a three-year grant of $3.15 million to the National FFA Organization in support of its commitment to shape future agriculture leaders.
INDIANAPOLIS, March 19, 2024 /PRNewswire-PRWeb/ -- Cargill awarded a three-year grant of $3.15 million to the National FFA Organization in support of its commitment to shape future agriculture leaders.
"We are honored to receive this grant from Cargill," said Molly Ball, president of the National FFA Foundation and chief marketing officer of the National FFA Organization.
The National FFA Organization is a school-based national youth leadership development organization of more than 945,000 student members as part of 9,163 local FFA chapters in all 50 states, Puerto Rico and the U.S. Virgin Islands.

AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer

Retrieved on:

Tuesday, March 5, 2024

This NDA is for taletrectinib as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously been treated with ROS1 TKIs.

Key Points:

This NDA is for taletrectinib as a first-line treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who have not previously been treated with ROS1 TKIs.
In 2023, China’s NMPA accepted taletrectinib’s first NDA and granted Priority Review Designation for adult patients with locally advanced or metastatic ROS1-positive NSCLC who have been previously treated with ROS1 TKIs.
Both NDAs in China are based on positive results from the Phase 2 TRUST-I (NCT04395677) trial.
“I am pleased this second NDA for taletrectinib has been accepted in China.

Coeur Announces Flow-Through Shares Private Placement to Advance Silvertip Exploration

Retrieved on:

Monday, February 26, 2024

Mining, Minerals, Natural Resources, Regulation, Person, Zinc, Income Tax Act, News, Sale, Lead, CDE, Silver, Offering, Security (finance)

Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) today announced that it has arranged a private placement (the “Offering”) of 7,704,725 flow-through common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “flow-through shares”) for gross proceeds of approximately $25 million (C$34 million), resulting in a 27% premium.

Key Points:

Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) today announced that it has arranged a private placement (the “Offering”) of 7,704,725 flow-through common shares of the Company that will qualify as “flow-through shares” within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the “flow-through shares”) for gross proceeds of approximately $25 million (C$34 million), resulting in a 27% premium.
The flow-through shares will be privately placed with investors in certain provinces in Canada pursuant to applicable exemptions from the prospectus requirements.
The flow-through shares will only be offered and sold outside the United States pursuant to Regulation S under the Securities Act of 1933, as amended (the “U.S.
Securities Act”).

Everest Medicines and Kezar Life Sciences Receive IND Approval from China NMPA for PALIZADE Trial in Lupus Nephritis

Retrieved on:

Monday, February 26, 2024

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).

Key Points:

Everest Medicines (HKEX 1952.HK) and Kezar Life Sciences, Inc. (Nasdaq: KZR) announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) approved Kezar’s investigational new drug (IND) application for initiation of the Phase 2b PALIZADE trial in China of zetomipzomib in patients with lupus nephritis (LN).
Everest will join Kezar and enroll patients in China as part of the ongoing PALIZADE trial, a global, placebo-controlled Phase 2b clinical trial evaluating the efficacy and safety of two dose levels of zetomipzomib or placebo in patients with active LN.
In September 2023, Everest obtained exclusive rights to develop and commercialize zetomipzomib in Greater China, South Korea and Southeast Asia.
“With the approval of the zetomipzomib IND in China, Everest now has three medicines in the renal space either commercialized or in clinical development.

Coeur Reports Year-End 2023 Mineral Reserves and Resources

Retrieved on:

Tuesday, February 20, 2024

Natural Resources, Manufacturing, Mining, Minerals, Steel, Zinc, Double, Growth, Lead, Metal, Gold, CDE, Silver, Wharf, Palladium

Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) today reported year-end 2023 proven and probable reserves of 3.2 million ounces of gold and 243.9 million ounces of silver, net of depletion.

Key Points:

Coeur Mining, Inc. (“Coeur” or the “Company”) (NYSE: CDE) today reported year-end 2023 proven and probable reserves of 3.2 million ounces of gold and 243.9 million ounces of silver, net of depletion.
Measured and indicated resources totaled 3.2 million ounces of gold, 196.3 million ounces of silver, 1,517 million pounds of zinc and 768.7 million pounds of lead, reflecting year-over-year increases for all metals driven by additions at Palmarejo, Rochester, Wharf and Silvertip.
Inferred resources were 2.0 million ounces of gold, 92.5 million ounces of silver, 481.8 million pounds of zinc and 199.8 million pounds of lead, signifying year-over-year increases of approximately 14%, 32%, 27% and 20%, respectively.
“Coeur’s total exploration investment in 2023 was lower than in recent years and resource expansion was our primary goal for the year, which was achieved across all of our sites.

NUS researchers invent new triple-junction tandem solar cells with world-record efficiency

Retrieved on:

Tuesday, March 5, 2024

Multimedia, Silicon, Assistant, Calibration, National university, CDE, NUS, Research, Renewable energy

Solar cells can be fabricated in more than two layers and assembled to form multi-junction solar cells to increase efficiency.

Key Points:

Solar cells can be fabricated in more than two layers and assembled to form multi-junction solar cells to increase efficiency.
When assessing performance, the NUS scientists found that perovskite solar cells incorporated with cyanate can achieve a higher voltage of 1.422 volts compared to 1.357 volts for conventional perovskite solar cells, with a significant reduction in energy loss.
The researchers also tested the newly engineered perovskite solar cell by continuously operating it at maximum power for 300 hours under controlled conditions.
The researchers stacked a perovskite solar cell and a silicon solar cell to create a dual-junction half-cell, providing an ideal base for the attachment of the cyanate-integrated perovskite solar cell.

Immunofoco Announces the Dual Approval of IND Applications by the U.S. FDA and China CDE for the First EpCAM CAR-T Targeted at Advanced Solid Tumors

Retrieved on:

Friday, February 23, 2024

IIT, ESMO, ASCO, FDA, GEJ, Acceptability, ODD, Stomach, GC, Society, GI, Bone marrow, Patient, Clinical trial, CDE, Oncology, IND, Chinese, Epithelial cell adhesion molecule, Pharmaceutical industry

SHANGHAI, Feb. 22, 2024 /PRNewswire/ -- Immunofoco, a company dedicated to developing cell therapy products for solid tumors, announced a significant milestone, that following the approval by the CDE in China for the clinical trial application of IMC001, an EpCAM-targeting autologous CAR-T cell product for infusion, it also received the IND approval from the U.S. FDA, for the treatment of EpCAM-positive advanced gastrointestinal tumors, including but not limited to advanced gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJ).

Key Points:

EpCAM serves as a biomarker for circulating tumor cells (CTCs), which is highly expressed in both primary and metastatic lesions of gastrointestinal tumors, while its expression in normal tissues is low.
IMC001, through targeting EpCAM, is the first CAR-T product utilizing the strategy of "curing the solid tumors by treating them as hematologic malignancies ".
She highlighted the significance of Immunofoco's achievement: securing dual IND approval for a second CAR-T product targeted for solid tumors in both the U.S. and China.
Targeting EpCAM shows great potential for CAR-T treatment of solid tumors as it is highly expressed in primary, metastatic and circulating tumor cells.

ProjectReady's New Construction Management Software Connects, Syncs, and Manages Construction Project Software Ecosystem

Retrieved on:

Wednesday, February 14, 2024

Cloud, Architecture, Multimedia, AEC, Information management, SharePoint, Risk, Dependent and independent variables, Ecosystem, CDE, Development, Software, Construction

WHITE PLAINS, N.Y., Feb. 14, 2024 /PRNewswire/ -- Leading provider of collaborative project information management software for the Architecture, Engineering, and Construction (AEC) industry, ProjectReady, announced it now connects and syncs data, drawings and files between multiple Autodesk Construction Cloud hubs, Procore companies, and SharePoint sites. The new construction management feature, "ReadyConnect," solves challenges that exists when multiple AEC companies on large-scale projects operate their own versions of the same Common Data Environment (CDE) but must collaborate on project information while maintaining the most accurate and current version of project-related content and data.

Key Points:

Connect, sync, and manage multiple Autodesk Construction Cloud hubs, Procore companies and SharePoint sites.
ProjectReady CEO Joe Giegerich said this development gives companies the ability to manage a project's extended software ecosystem.
"There's a lot more to project and program management than maintaining a schedule," said Giegerich.
"The management and successful delivery of complex construction projects requires architects, engineers, general contractors, subcontractors, and vendors, to eliminate software silos.

New OmniSYS | XiFin Pharmacy Transformation Study on Future of the Industry Reveals Reimbursement a Top Concern, Even as Service and Expanded Role Opportunities Identified

Retrieved on:

Wednesday, February 14, 2024

Launched in November 2023, the study delved into pharmacy expansion, garnering key insights from more than 500 respondents representing a wide array of pharmacy professionals and organizations.

Key Points:

Launched in November 2023, the study delved into pharmacy expansion, garnering key insights from more than 500 respondents representing a wide array of pharmacy professionals and organizations.
(Graphic: Business Wire)
Nearly 75% of respondents tagged an expanded role for pharmacists to fill the primary care gaps as a top growth opportunity.
However, over 70% of these respondents reported that reimbursement was a barrier to expansion, while 61% said medical billing capabilities were.
Barriers to Expansion: Reimbursement challenges, staff shortages, and regulatory limitations were identified as significant barriers to clinical service expansion.

Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl

Retrieved on:

Friday, February 9, 2024

SAN, CRC, FDA, Part, MSS, Safety, Colorectal cancer, Pembrolizumab, Merck, Patient, CDE, Merck & Co., Pharmaceutical industry

SAN DIEGO and SUZHOU, China, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced progress and expansion of the clinical collaboration development program for its masked, anti-CTLA-4 SAFEbody, ADG126 in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in patients with metastatic microsatellite-stable (MSS) colorectal cancer (CRC).

Key Points:

Given the safety profile of ADG126, Adagene has also initiated evaluation of 20 mg/kg loading doses in combination with pembrolizumab in patients with advanced/metastatic cancer.
The company plans dose expansion with this regimen in patients with MSS CRC in the US and Asia Pacific.
Adagene has also received clearance from the CDE in China to initiate clinical evaluation of ADG126 in combination with pembrolizumab.
Data from the ongoing phase 1b/2 clinical trial of ADG126 in combination with pembrolizumab, including dose expansion cohorts, are anticipated throughout 2024:
Evaluation of 20 mg/kg loading doses for Project Optimus requirements: